InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,180.74
(
1.03%
)
US TECH 100
17,602.00
(
1.05%
)
Dow Jones
38,852.27
(
0.46%
)
Brent Oil
83.39
(
0.32%
)
Bitcoin
63,598.00
(
-0.63%
)
Post# of 10835
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Robertscott

Send PM Follow Ignore
Followers 97
Posts 128742
Boards Moderated 1
Alias Born 07/24/2016

Robertscott

Re: None

Thursday, 02/16/2017 11:09:44 AM

Thursday, February 16, 2017 11:09:44 AM

Post# of 10835

$IMLFF InMed is initially targeting Epidermolysis Bullosa (EB) and Glaucoma with specific cannabinoid compounds that have shown promise in early studies. EB is an orphan condition that has no currently approved treatments, which could pave the way for faster regulatory approvals and a dramatic improvement in patient quality of life. Glaucoma is the second leading cause of blindness in the developed world.

https://finance.yahoo.com/news/inmed-pharma-ceo-discusses-companys-140000706.html

$VBIO $GWPH $AXIM
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up